期刊
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
卷 24, 期 2, 页码 -出版社
MDPI
DOI: 10.3390/ijms24021321
关键词
hedgehog signaling; tumor microenvironment; immunosuppression; immune evasion; immune checkpoint inhibitors; combination therapy
Hedgehog-GLI signaling is important in embryogenesis and tissue homeostasis and its aberrant activation is involved in various cancers. Targeted inhibition of the pathway is a potential treatment strategy. Recent studies have also shown its role in tumor immune evasion and poor responses to cancer immunotherapy.
Hedgehog-GLI (HH) signaling plays an essential role in embryogenesis and tissue homeostasis. Aberrant activation of the pathway through mutations or other mechanisms is involved in the development and progression of numerous types of cancer, including basal cell carcinoma, medulloblastoma, melanoma, breast, prostate, hepatocellular and pancreatic carcinomas. Activation of HH signaling sustains proliferation, suppresses cell death signals, enhances invasion and metastasis, deregulates cellular metabolism and promotes angiogenesis and tumor inflammation. Targeted inhibition of the HH pathway has therefore emerged as an attractive therapeutic strategy for the treatment of a wide range of cancers. Currently, the Smoothened (SMO) receptor and the downstream GLI transcriptional factors have been investigated for the development of targeted drugs. Recent studies have revealed that the HH signaling is also involved in tumor immune evasion and poor responses to cancer immunotherapy. Here we focus on the effects of HH signaling on the major cellular components of the adaptive and innate immune systems, and we present recent discoveries elucidating how the immunosuppressive function of the HH pathway is engaged by cancer cells to prevent immune surveillance. In addition, we discuss the future prospect of therapeutic options combining the HH pathway and immune checkpoint inhibitors.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据